Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).
Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, Bota S, Monnet I, Chajara A, Robinet G. Barlesi F, et al. Ann Oncol. 2011 Nov;22(11):2466-2470. doi: 10.1093/annonc/mdr003. Epub 2011 Feb 14. Ann Oncol. 2011. PMID: 21321089 Free article. Clinical Trial.
[Toward the multidisciplinary management of brain metastasis].
Carpentier A, Gonçalves A, Azria D, Barlesi F, Métellus P, Spano JP, Tallet A; Groupe de réflexion pour la prise en charge des métastases cérébrales (GRPC MaC). Carpentier A, et al. Among authors: barlesi f. Bull Cancer. 2013 Jan 1;100(1):5. doi: 10.1684/bdc.2012.1685. Bull Cancer. 2013. PMID: 23360733 Free article. French. No abstract available.
[Management of brain metastases for lung cancer patients].
Barlesi F, Khobta N, Tallet A, Goncalves A, Azria D, Spano JP, Carpentier AF, Régis J, Metellus P. Barlesi F, et al. Bull Cancer. 2013 Mar;100(3):303-8. doi: 10.1684/bdc.2013.1721. Bull Cancer. 2013. PMID: 23518334 French.
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC. Zimmer L, et al. Among authors: barlesi f. Clin Cancer Res. 2014 Aug 15;20(16):4251-61. doi: 10.1158/1078-0432.CCR-14-0341. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947927 Clinical Trial.
[Global brain metastases management strategy: a multidisciplinary-based approach].
Métellus P, Tallet A, Dhermain F, Reyns N, Carpentier A, Spano JP, Azria D, Noël G, Barlési F, Taillibert S, Le Rhun É. Métellus P, et al. Among authors: barlesi f. Cancer Radiother. 2015 Feb;19(1):61-5. doi: 10.1016/j.canrad.2014.11.009. Epub 2015 Jan 31. Cancer Radiother. 2015. PMID: 25649388 Review. French.
[Systemic treatment of brain metastases from lung cancer].
Barlesi F, Spano JP, Cortot AB, Carpentier AF, Robinet G, Besse B. Barlesi F, et al. Cancer Radiother. 2015 Feb;19(1):43-7. doi: 10.1016/j.canrad.2014.12.001. Epub 2015 Feb 2. Cancer Radiother. 2015. PMID: 25656857 Review. French.
[The management of bone metastasis].
Bonetto R, Tallet A, Mélot A, Calderon B, Barlesi F. Bonetto R, et al. Among authors: barlesi f. Bull Cancer. 2017 Jun;104(6):585-592. doi: 10.1016/j.bulcan.2017.02.004. Epub 2017 Apr 6. Bull Cancer. 2017. PMID: 28391985 Review. French.
458 results